Global Blood and Plasma Components Market Report 2022: A $66.47 Billion Market in 2031

company logo

Global blood and plasma components market

Global blood and plasma components market

Global blood and plasma components market

Dublin, June 10, 2022 (GLOBE NEWSWIRE) — The report “Blood and Plasma Components Market – A Global and Regional Analysis: Focus on Product, Application, End User and Region – Analysis and Forecast, 2021- 2031” has been added to from offer.

The global blood and plasma components market is expected to reach USD 66.47 billion in 2031 from USD 39.58 billion in 2020, growing at a CAGR of 4.90% during the forecast period 2021-2031.

The global blood and plasma components market is expected to witness minimal growth, owing to the growing burden of primary immunodeficiency diseases such as hemophilia A, von Willebrand disease (vWD) and secondary immunodeficiency diseases.

Additionally, the growing burden of cancer, hematological malignancies, and organ transplantation are also contributing to the growth of the market. An increase in research and development on the use of plasma components for the treatment of neurological disorders such as chronic inflammatory demyelinating polyneuropathy (CIDP) is also driving the growth of the market.

Moreover, the initiatives taken by the major players in the global blood and plasma components market to expand and launch more blood and plasma collection centers across the globe to cater the supply of blood and plasma components are the major factors that are expected to fuel the growth of the market.

Competitive landscape

The global blood and plasma components market includes well-established companies along with a few emerging ones. Several companies in the global blood and plasma components market are trying to expand their presence in the market by undertaking business expansion activities such as launching new blood and plasma collection centers in new locations.

In addition, companies are constantly working on research and development to expand the indications of plasma-derived products already on the market. The major players in the global blood and plasma components market witnessed major business expansion, product approvals, and synergistic activities in the market during the period January 2018-January 2022.

The inclination of companies towards product approvals, synergistic activities and business expansion activities suggests that companies are constantly striving to explore the potential of blood and plasma components for new application areas and to offer products to meet the growing demand for blood and plasma components.

Key Questions Answered by the Report

  • How are blood and plasma components revolutionizing the landscape of hematology and solid tumor management?

  • What are the key market drivers, challenges and opportunities in the Global Blood and Plasma Components Market?

  • What are the underlying structures resulting from the emerging trends in the global blood and plasma components market?

  • What has been the impact of the COVID-19 pandemic on the global blood and plasma component ecosystem?

  • What are the key development strategies implemented by the major players to stay in the competitive market?

  • What are the main regulatory implications in developed and developing regions regarding the use of blood and plasma components?

  • What are the potential entry barriers faced by companies wishing to enter a particular market region?

  • What will be the growth rate of the global blood and plasma components market during the forecast period?

  • How is each segment of the market expected to grow during the forecast period 2021-2031 and what revenue is expected to be generated by each of the segments?

  • What are the growth opportunities for blood and plasma component companies in their region of operation?

  • Who are the leading players with major deals in the Global Blood and Plasma Components Market?

  • Which companies are expected to be highly disruptive in the future, and why?

Main topics covered:

1 Markets
1.1 Product Definition
1.1.1 Inclusion and exclusion criteria
1.2 Market Scope
1.2.1 Scope of the study
1.2.2 Key questions answered by the report
1.3 Research methodology
1.3.1 Global Blood and Plasma Components Market: Research Methodology
1.3.2 Data sources Primary data sources Secondary data sources
1.3.3 Market estimation model
1.3.4 Business profiling criteria
1.4 Market Overview
1.4.1 Red blood cells
1.4.2 Pads
1.4.3 Plasma
1.4.4 Granulocytes
1.5 Historical trends in the use of blood components
1.6 Use of blood components
1.7 Market Footprint and Future Potential, USD Million, 2020-2031

2 Industry Analysis
2.1 Overview
2.2 Regulatory framework
2.2.1 Regulatory framework in the United States
2.2.2 Regulatory framework in the European Union
2.2.3 Regulatory framework in Asia-Pacific China Japan
2.3 Supply Chain Analysis
2.4 Impact of COVID-19 on the Global Blood and Plasma Components Market

3 Market dynamics
3.1 Overview
3.2 Impact analysis
3.3 Market Drivers
3.3.1 Global Increase in Patients with Blood Disorders
3.3.2 Increase in the number of trauma patients and chronic illnesses
3.3.3 Increased number of product launches and approvals
3.4 Market Constraints
3.4.1 Risk of infectious diseases transmitted by transfusion and adverse effects associated with blood transfusion
3.4.2 Long duration of the manufacturing process and strict regulatory guidelines
3.5 Market opportunities
3.5.1 Increased adoption of business expansion strategies in the market

4 Competitive landscape
4.1 Overview
4.2 Business Strategies
4.2.1 Mergers and Acquisitions
4.2.2 Synergistic activities
4.2.3 Business expansion, funding and reimbursement activities
4.3 Business Strategies
4.3.1 Product launches
4.3.2 Product Approvals
4.4 Market Share Analysis, by Company (2020)
4.5 Growth Share Analysis

5 products, million dollars, 2020-2031
5.1 Overview
5.2 Transfusion market
5.2.1 Concentrated red blood cells
5.2.2 Platelet products
5.2.3 Frozen plasma
5.3 Plasma-derived products
5.3.1 Immunoglobulins Intravenous immunoglobulins Subcutaneous immunoglobulins Other immunoglobulins
5.3.2 Clotting factor concentrates Coagulation factor VIII concentrate Coagulation factor IX concentrate Von Willebrand Factor (vWF) Prothrombin complex concentrates Clotting factor XIII concentrate
5.3.3 Albumins
5.3.4 Proteinase inhibitors
5.3.5 Other blood derivatives

6 Demand, USD million, 2020-2031
6.1 Overview
6.2 Hematology
6.2.1 Hemoglobinopathy Thalassemia Sickle cell disease Platelet refractory
6.2.2 Management of hematological malignancies
6.2.3 Coagulopathy Hemophilia Von Willebrand disease Thrombosis Thrombocytopenia
6.3 Management of solid tumors
6.4 Others
6.5 Emerging fields of application

7 end users, billions of dollars, 2020-2031
7.1 Overview
7.2 Hospitals and specialized clinics
7.3 Research institutions
7.4 Diagnostic laboratories
7.5 Other end users

8 Region, millions of dollars, 2020-2031
8.1 Overview
8.2 North America
8.2.1 United States
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 United Kingdom
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia-Pacific
8.4.1 China
8.4.2 India
8.4.3 Japan
8.4.4 Australia
8.4.5 South Korea
8.4.6 Singapore
8.4.7 Rest of Asia-Pacific
8.5 Rest of the world

9 Market – Competitive Benchmarking and Company Profiles

  • CSL Limited

  • Grifols, SA

  • ADMA Biologics, Inc.

  • Takeda Pharmaceutical Company Limited

  • GC-Pharma

  • Octapharma S.A.

  • Kedrion SpA

  • Emergent BioSolutions Inc.

  • Organic Products Laboratory Ltd.

  • LFB SA

  • American Red Cross

  • Versiti, Inc.

  • Blood Centers of America

  • Carter BloodCare

  • Memorial Blood Centers

For more information about this report visit


CONTACT: CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Source link

Richard V. Johnson